{"id":74968,"date":"2026-08-17T13:06:53","date_gmt":"2026-08-17T05:06:53","guid":{"rendered":"https:\/\/flcube.com\/?p=74968"},"modified":"2026-08-17T13:06:55","modified_gmt":"2026-08-17T05:06:55","slug":"chongqing-pharscin-wins-china-clinical-trial-approval-for-oric-1327-in-glaucoma-and-ocular-hypertension","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=74968","title":{"rendered":"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Chongqing Pharscin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/002907:SHE\">SHE: 002907<\/a>) announced that its drug candidate <strong>ORIC\u20111327<\/strong> has received <strong>clinical trial approvals in China<\/strong> for the treatment of <strong>glaucoma<\/strong> and <strong>ocular hypertension<\/strong>. The clearance clears the path for first\u2011in\u2011human studies of the company&#8217;s ophthalmology pipeline candidate.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>China NMPA<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ORIC\u20111327 (selective small\u2011molecule inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Glaucoma and ocular hypertension<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>13 Aug 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Initiation of clinical trials in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>ORIC\u20111327<\/strong>, a <strong>selective small\u2011molecule inhibitor<\/strong> with <strong>full proprietary intellectual property rights<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> Intended for the treatment of patients with <strong>glaucoma<\/strong> and <strong>ocular hypertension<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Designed to lower <strong>intraocular pressure (IOP)<\/strong>, the principal modifiable risk factor in glaucoma<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Fully proprietary to <strong>Chongqing Pharscin Pharmaceutical<\/strong>, supporting independent development and commercialization rights<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-evidence\" class=\"wp-block-heading\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Animal Models<\/strong><\/td><td>New Zealand rabbits and cynomolgus monkeys<\/td><\/tr><tr><td><strong>Efficacy Readout<\/strong><\/td><td><strong>Significant intraocular pressure\u2011lowering effects<\/strong><\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Favorable ocular safety profile<\/td><\/tr><tr><td><strong>Conclusion<\/strong><\/td><td>Promising drugability prospects supporting clinical advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Preclinical studies in two relevant species demonstrated that <strong>ORIC\u20111327<\/strong> delivers statistically meaningful reductions in intraocular pressure while maintaining favorable ocular tolerability \u2014 a combination that supports its progression into clinical development.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Burden:<\/strong> Glaucoma is one of the leading causes of irreversible blindness worldwide, and ocular hypertension is its most important modifiable risk factor, creating a large chronic\u2011therapy market.<\/li>\n\n\n\n<li><strong>Mechanism Differentiation:<\/strong> A selective small\u2011molecule approach to IOP reduction could complement or compete with existing prostaglandin analogs, beta\u2011blockers, and Rho\u2011kinase inhibitors, particularly for patients with inadequate response or tolerability issues.<\/li>\n\n\n\n<li><strong>Pipeline Momentum:<\/strong> The clinical trial approval validates <strong>Chongqing Pharscin&#8217;s<\/strong> ophthalmology platform and extends its innovative portfolio beyond established franchises.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> With full proprietary IP, <strong>ORIC\u20111327<\/strong> gives Pharscin full control over development and potential partnership leverage in the fast\u2011growing glaucoma therapeutic market.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, trial outcomes, and commercial potential for ORIC\u20111327. Actual results may differ due to risks including clinical trial results, regulatory decisions, and competitive dynamics in the ophthalmology market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-26b6eb95-05ac-4353-ac16-9d87156993d7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\">\u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-26b6eb95-05ac-4353-ac16-9d87156993d7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC\u20111327 has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,44,3665,3666],"class_list":["post-74968","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-ophthalmology","tag-pharscin-pharmaceutical","tag-she-002907"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC\u20111327 has received clinical trial approvals in China for the treatment of glaucoma and ocular hypertension. The clearance clears the path for first\u2011in\u2011human studies of the company&#039;s ophthalmology pipeline candidate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=74968\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension\" \/>\n<meta property=\"og:description\" content=\"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC\u20111327 has received clinical trial approvals in China for the treatment of glaucoma and ocular hypertension. The clearance clears the path for first\u2011in\u2011human studies of the company&#039;s ophthalmology pipeline candidate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=74968\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T05:06:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-17T05:06:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74968#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74968\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension\",\"datePublished\":\"2026-08-17T05:06:53+00:00\",\"dateModified\":\"2026-08-17T05:06:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74968\"},\"wordCount\":366,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Ophthalmology\",\"Pharscin Pharmaceutical\",\"SHE: 002907\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74968#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74968\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=74968\",\"name\":\"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-17T05:06:53+00:00\",\"dateModified\":\"2026-08-17T05:06:55+00:00\",\"description\":\"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC\u20111327 has received clinical trial approvals in China for the treatment of glaucoma and ocular hypertension. The clearance clears the path for first\u2011in\u2011human studies of the company's ophthalmology pipeline candidate.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74968#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74968\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74968#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension - Insight, China&#039;s Pharmaceutical Industry","description":"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC\u20111327 has received clinical trial approvals in China for the treatment of glaucoma and ocular hypertension. The clearance clears the path for first\u2011in\u2011human studies of the company's ophthalmology pipeline candidate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=74968","og_locale":"en_US","og_type":"article","og_title":"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension","og_description":"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC\u20111327 has received clinical trial approvals in China for the treatment of glaucoma and ocular hypertension. The clearance clears the path for first\u2011in\u2011human studies of the company's ophthalmology pipeline candidate.","og_url":"https:\/\/flcube.com\/?p=74968","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-17T05:06:53+00:00","article_modified_time":"2026-08-17T05:06:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=74968#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=74968"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension","datePublished":"2026-08-17T05:06:53+00:00","dateModified":"2026-08-17T05:06:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=74968"},"wordCount":366,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Ophthalmology","Pharscin Pharmaceutical","SHE: 002907"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=74968#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=74968","url":"https:\/\/flcube.com\/?p=74968","name":"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-17T05:06:53+00:00","dateModified":"2026-08-17T05:06:55+00:00","description":"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC\u20111327 has received clinical trial approvals in China for the treatment of glaucoma and ocular hypertension. The clearance clears the path for first\u2011in\u2011human studies of the company's ophthalmology pipeline candidate.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=74968#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=74968"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=74968#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chongqing Pharscin Wins China Clinical Trial Approval for ORIC\u20111327 in Glaucoma and Ocular Hypertension"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=74968"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74968\/revisions"}],"predecessor-version":[{"id":74972,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74968\/revisions\/74972"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=74968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=74968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=74968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}